Fluticasone furoate/umeclidinium bromide/vilanterol

Last updated

Fluticasone furoate/umeclidinium bromide/vilanterol
Combination of
Fluticasone furoate Corticosteroid
Umeclidinium bromide Muscarinic antagonist
Vilanterol Ultra-long-acting β2 agonist
Clinical data
Trade names Trelegy Ellipta, Elebrato Ellipta, Temybric Ellipta
Other namesFF/UMEC/VI
AHFS/Drugs.com Professional Drug Facts
MedlinePlus a618017
License data
Pregnancy
category
Routes of
administration 		Inhalation
ATC code
Legal status
Legal status
Identifiers
CAS Number
KEGG

Fluticasone furoate/umeclidinium bromide/vilanterol, sold under the brand name Trelegy Ellipta among others, is a fixed-dose combination inhaled medication that is used for the maintenance treatment of chronic obstructive pulmonary disease (COPD). [6] [7] The medications work in different ways: fluticasone furoate is an inhaled corticosteroid (ICS), umeclidinium is a long-acting muscarinic antagonist (LAMA), and vilanterol is a long-acting beta-agonist (LABA).

Contents

In 2020, it was the 224th most commonly prescribed medication in the United States, with more than 2 million prescriptions. [8] [9]

Medical uses

The combination fluticasone furoate/umeclidinium bromide/vilanterol product is approved by the United States Food and Drug Administration with an indication for the maintenance treatment of a chronic lung problem called chronic obstructive pulmonary disease (COPD) in adults who (1) have already tried fluticasone furoate/vilanterol (brand name Breo Ellipta) but are still experiencing symptoms of airway obstruction or who want to reduce the risk for COPD exacerbations and (2) are already receiving umeclidinium and fluticasone furoate/vilanterol and would like to consolidate their inhaler therapy into a single product. [4] Similarly, in the European Union, FF/UMEC/VI is indicated for the maintenance treatment in adults with moderate to severe COPD who are not adequately treated by an inhaled corticosteroid (ICS) plus long-acting beta-agonist (LABA) combination or a LABA plus long-acting muscarinic antagonist (LAMA) combination. [5] Because FF/UMEC/VI is for maintenance (chronic prophylaxis) treatment, it is not used when people are experiencing acute symptoms consistent with worsening airway obstruction (i.e. COPD exacerbation or an asthma exacerbation). [4]

The 2018 National Institute for Health and Care Excellence (NICE) guidelines recommend consideration for ICS/LABA/LAMA triple therapy (like FF/UMEC/VI) provided that the person with COPD has received optimal non-pharmacologic management (e.g. smoking cessation), is experiencing acute COPD exacerbations (either 1 severe exacerbation leading to hospitalization or 2 moderate exacerbations within 1 year), and their COPD has worsened their quality of life. [10] The 2020 Global Initiative for Chronic Obstructive Lung Disease (GOLD) guidelines recommend consideration for triple therapy for people with COPD that—despite ICS/LABA therapy—are persistently breathless, cannot exercise due to their symptoms, or develop further exacerbations. [11]

Available forms

Fluticasone furoate/umeclidinium bromide/vilanterol is only available as an inhaler, which generally contains thirty doses (one-month supply) of medicated powder for inhalation (except in the case of, e.g., sample products from the manufacturer or those produced specifically for hospitals [institutional formulations], which contain 14 doses). [4] FF/UMEC/VI exists as a dry-powder inhaler, which means that the force of the user's breath causes the medicated powder to leave the device and enter the lungs [4] (unlike, e.g., a metered-dose inhaler which includes a propellant). [12]

Contraindications

Fluticasone furoate/umeclidinium bromide/vilanterol is contraindicated in people who are allergic to any of the individual medication components (i.e. an allergy to vilanterol precludes use of the combination product) or who are severely allergic to milk proteins. [4] This is because each dose of FF/UMEC/VI is formulated with lactose monohydrate (a sugar found in milk), a portion of which contains detectable milk proteins. [4]

Adverse effects

The adverse effects of fluticasone furoate/umeclidinium bromide/vilanterol include those that are characteristic of its individual components. For example, there is a risk for anticholinergic side effects (e.g. difficulty urinating) due to umeclidinium. Effects on the cardiovascular system, such as increased pulse, elevated blood pressure, and abnormal heart rhythms, can occur due to vilanterol. Fluticasone furoate, as an inhaled corticosteroid (ICS), can cause side effects that are characteristic of corticosteroids, such as decreased bone mineral density, adrenal suppression (decreased production of corticosteroids in the body), and a weakened immune system. [4] There is an elevated risk of pneumonia (a type of serious lung infection) with FF/UMEC/VI; in clinical trials, there was a 1.53-fold higher risk of pneumonia in people that received FF/UMEC/VI or FF/VI instead of UMEC/VI (which does not include fluticasone furoate, an ICS). [13]

Interactions

Fluticasone furoate/umeclidinium bromide/vilanterol may have drug–drug interactions (DDIs) that are both pharmacokinetic (related to metabolism) and pharmacodynamic (related to the effect of medications) in nature. FF/UMEC/VI is susceptible to DDIs that would normally arise from any of the individual components of the medication.[ citation needed ]

Pharmacokinetic interactions

All three components are substrates of the efflux transporter p-glycoprotein (p-gp), [4] a protein that causes drugs to be transported out of cells. The presence of p-gp inhibiting drugs did not appear to effect the pharmacokinetics of vilanterol, though the area under the curve (a measure of systemic absorption) of umeclidinium increased 1.4-fold. The effect of p-gp inhibitors on fluticasone pharmacokinetics are unknown. [4]

Fluticasone furoate

Fluticasone furoate is metabolized by cytochrome P450 3A4 (CYP3A4). [4] Medications that are inhibitors of CYP3A4 (e.g. ketoconazole) may decrease fluticasone's metabolism in the body, causing levels to accumulate. The bioavailability (the amount of a medication that reaches the blood after administration) of fluticasone in the FF/UMEC/VI product is low (15.2%), [4] decreasing the risk of acute toxicity in overdose/accumulation situations. However, if a person is exposed to high doses of fluticasone over time, it may increase their risk of experiencing Cushing's syndrome [4] (a syndrome that occurs due to high levels of glucocorticoids, like fluticasone, and includes muscular weakness, weight gain, and excessive hairiness). In drug interaction studies of FF/UMEC/VI in the presence of the CYP3A4 inhibitor ketoconazole, adrenal insufficiency (as measured by serum cortisol levels was noted at 24 hours (27% decrease in cortisol). [4]

Umeclidinium bromide

Umeclidinium is primarily metabolized by CYP2D6, in addition to a few secondary metabolism pathways (e.g. glucuronidation). [4] At doses of umeclidinium that are above the recommended doses, no clinically significant differences in blood levels of umeclidinium was found after repeated dosing in people with impaired CYP2D6 function (compared to people with normal CYP2D6 function). [4]

Vilanterol

Vilanterol is also a CYP3A4 substrate. [4] Like fluticasone, CYP3A4 inhibitors may increase the levels of vilanterol in the body. [4] In drug interaction studies of FF/UMEC/VI in the presence of the CYP3A4 inhibitor ketoconazole, side effects that are characteristic of vilanterol overdose were not observed (i.e. elevated heart rate). [4]

Pharmacodynamic interactions

Fluticasone furoate

Fluticasone furoate is a corticosteroid, a type of hormone that can suppress the function of the immune system (which fights off infections). [4] This can increase the risk of infection, especially oral fungal infections when people do not rinse out their mouths with water after using fluticasone. [4] Combining fluticasone with other steroids (e.g. oral prednisone) may theoretically increase the risk of infections. [14]

Umeclidinium bromide

Umeclidinium is a medication with anticholinergic properties. When combined with other medication that also antagonize cholinergic receptors, this may lead to a duplicate anticholinergic effect, increasing the risk for anticholinergic spectrum side effects (e.g. dry mouth, constipation). [4]

Vilanterol

Vilanterol is a beta2-adrenergic receptor agonist. When combined with medications that have the opposite effect (i.e. beta blockers, like carvedilol), this may theoretically prevent vilanterol from working as intended. [4]

Pharmacology

Fluticasone furoate/umeclidinium bromide/vilanterol is a combination product made up of three medications: [4] [15] [16] [5]

In the setting of chronic obstructive pulmonary disease (COPD), an inhaled corticosteroid (ICS) will reduce inflammation while a long-acting muscarinic antagonist (LAMA) and a long-acting beta-agonist (LABA) will cause bronchodilation (widening and opening of the bronchi, the airways of the lungs). [4] Because LABAs and LAMAs are "long-acting", they are not used for acute problems with breathing. [4]

Chemistry

Fluticasone furoate

Fluticasone furoate Fluticasone propionate Fluticasone
Chemical structure Fluticasone furoate.svg Fluticasone propionate.svg Fluticasone.svg

Fluticasone furoate, like fluticasone propionate, is a synthetic corticosteroid that is derived from fluticasone (another synthetic corticosteroid). [17] [18]

Umeclidinium bromide

Umeclidinium bromide
Chemical structure Umeclidinium bromide.svg

Umeclidinium bromide is the bromide (Br−1) salt form of umeclidinium, which contains a quaternary ammonium compound. [19]

Vilanterol

Vilanterol
Chemical structure Vilanterol.svg

Vilanterol is a 1,3-dichlorobenzene derivative. [20]

History

Fluticasone furoate/umeclidinium bromide/vilanterol was approved for medical use in the United States and in the European Union in 2017. [6] [15] [3] [16] It was approved in the European Union with an additional indication in June 2019. [5]

Due to the COVID-19 pandemic, a meeting of the Pulmonary-Allergy Drugs Advisory Committee (PADAC) of the U.S. Food and Drug Administration (FDA) scheduled for April 2020, on the subject of FF/UMEC/VI was postponed indefinitely. [21] The Advisory Committee had planned to discuss the manufacturer's claim that the medication reduces all-cause mortality in people with COPD. [21] FF/UMEC/VI was one of many medications whose regulatory status was affected by the pandemic. [22]

See also

Related Research Articles

<span class="mw-page-title-main">Salmeterol</span> Chemical compound

Salmeterol is a long-acting β2 adrenergic receptor agonist (LABA) used in the maintenance and prevention of asthma symptoms and maintenance of chronic obstructive pulmonary disease (COPD) symptoms. Symptoms of bronchospasm include shortness of breath, wheezing, coughing and chest tightness. It is also used to prevent breathing difficulties during exercise.

<span class="mw-page-title-main">Budesonide/formoterol</span> Management of asthma & chronic obstructive pulmonary disease

Budesonide/formoterol, sold under the brand name Symbicort among others, is a fixed-dose combination medication used in the management of asthma or chronic obstructive pulmonary disease (COPD). It contains budesonide, a steroid and formoterol, a long-acting β2-agonist (LABA). The product monograph does not support its use for sudden worsening or treatment of active bronchospasm. However, a 2020 review of the literature does support such use. It is used by breathing in the medication.

<span class="mw-page-title-main">Formoterol</span> Chemical compound

Formoterol, also known as eformoterol, is a long-acting β2 agonist (LABA) used as a bronchodilator in the management of asthma and chronic obstructive pulmonary disease (COPD). Formoterol has an extended duration of action compared to short-acting β2 agonists such as salbutamol (albuterol), which are effective for 4 h to 6 h. Formoterol has a relatively rapid onset of action compared to other LABAs, and is effective within 2-3 minutes. The 2022 Global Initiative for Asthma report recommends a combination formoterol/inhaled corticosteroid inhaler as both a preventer and reliever treatment for asthma in adults. In children, a short-actingβ2 agonist is still recommended.

<span class="mw-page-title-main">Inhaler</span> Medical device

An inhaler is a medical device used for delivering medicines into the lungs through the work of a person's breathing. This allows medicines to be delivered to and absorbed in the lungs, which provides the ability for targeted medical treatment to this specific region of the body, as well as a reduction in the side effects of oral medications. There are a wide variety of inhalers, and they are commonly used to treat numerous medical conditions with asthma and chronic obstructive pulmonary disease (COPD) being among the most notable.

Beta<sub>2</sub>-adrenergic agonist Compounds that bind to and activate adrenergic beta-2 receptors

Beta2-adrenergic agonists, also known as adrenergic β2 receptor agonists, are a class of drugs that act on the β2 adrenergic receptor. Like other β adrenergic agonists, they cause smooth muscle relaxation. β2 adrenergic agonists' effects on smooth muscle cause dilation of bronchial passages, vasodilation in muscle and liver, relaxation of uterine muscle, and release of insulin. They are primarily used to treat asthma and other pulmonary disorders. Bronchodilators are considered an important treatment regime for Chronic obstructive pulmonary disease (COPD) and are usually used in combination with short acting medications and long acting medications in a combined inhaler.

<span class="mw-page-title-main">Bronchoconstriction</span> Constriction of the terminal airways in the lungs

Bronchoconstriction is the constriction of the airways in the lungs due to the tightening of surrounding smooth muscle, with consequent coughing, wheezing, and shortness of breath.

<span class="mw-page-title-main">Long-acting beta-adrenoceptor agonist</span> Drug prescribed for asthma patients

Long-acting β adrenoceptor agonists are usually prescribed for moderate-to-severe persistent asthma patients or patients with chronic obstructive pulmonary disease (COPD). They are designed to reduce the need for shorter-acting β2 agonists such as salbutamol (albuterol), as they have a duration of action of approximately 12 hours in comparison with the 4-to-6-hour duration of salbutamol, making them candidates for sparing high doses of corticosteroids or treating nocturnal asthma and providing symptomatic improvement in patients with COPD. With the exception of formoterol, long-acting β2 agonists are not recommended for the treatment of acute asthma exacerbations because of their slower onset of action compared to salbutamol. Their long duration of action is due to the addition of a long, lipophilic side-chain that binds to an exosite on adrenergic receptors. This allows the active portion of the molecule to continuously bind and unbind at β2 receptors in the smooth muscle in the lungs.

<span class="mw-page-title-main">Fluticasone furoate</span> Chemical compound

Fluticasone furoate, sold under the brand name Flonase Sensimist among others, is a corticosteroid for the treatment of non-allergic and allergic rhinitis administered by a nasal spray. It is also available as an inhaled corticosteroid to help prevent and control symptoms of asthma. It is derived from cortisol. Unlike fluticasone propionate, which is only approved for children four years and older, fluticasone furoate is approved in children as young as two years of age when used for allergies.

<span class="mw-page-title-main">Aclidinium bromide</span> Chemical compound

Aclidinium bromide (INN) is a long-acting, inhaled muscarinic antagonist (LAMA) approved in the United States on July 24, 2012 as a maintenance treatment for chronic obstructive pulmonary disease (COPD).

<span class="mw-page-title-main">Tiotropium bromide</span> Long-acting bronchodilator in the maintenance of COPD and asthma

Tiotropium bromide, sold under the brand name Spiriva among others, is a long-acting bronchodilator used in the management of chronic obstructive pulmonary disease (COPD) and asthma. Specifically it is used during periods of breathing difficulty to prevent them from getting worse, rather than to prevent them from happening. It is used by inhalation through the mouth. Onset typically begins within half an hour and lasts for 24 hours.

<span class="mw-page-title-main">Vilanterol</span> Asthma drug – β2 adrenoreceptor agonist

Vilanterol is an ultra-long-acting β2 adrenoreceptor agonist (ultra-LABA), which was approved in May 2013 in combination with fluticasone furoate for sale as Breo Ellipta by GlaxoSmithKline for the treatment of chronic obstructive pulmonary disease (COPD).. The combination is also approved for the treatment of asthma in Canada, Europe, Japan and New Zealand.

<span class="mw-page-title-main">Fluticasone furoate/vilanterol</span> Pharmaceutical drug formulation

Fluticasone furoate/vilanterol (FF/VI), sold under the brand name Breo Ellipta among others, is a combination medication for the treatment of chronic obstructive pulmonary disease (COPD) and asthma. It contains fluticasone furoate, an inhaled corticosteroid, and vilanterol, an ultra-long-acting β2 agonist (ultra-LABA).

<span class="mw-page-title-main">Umeclidinium bromide</span> Chemical compound

Umeclidinium bromide, sold under the brand name Incruse Ellipta, is a long-acting muscarinic antagonist approved for the maintenance treatment of chronic obstructive pulmonary disease (COPD). It is also approved for this indication in combination with vilanterol and also as a triple-therapy combination as fluticasone furoate/umeclidinium bromide/vilanterol.

<span class="mw-page-title-main">Umeclidinium bromide/vilanterol</span> Pharmaceutical drug

Umeclidinium bromide/vilanterol, sold under the brand name Anoro Ellipta, among others, is a fixed-dose combination medication for the treatment of chronic obstructive pulmonary disease (COPD). It is administered by inhalation.

Ellipta is part of GlaxoSmithKline's trade names of several inhalable asthma and chronic obstructive airway disease (COPD) combination medications that make use of the same type of inhaler:

<span class="mw-page-title-main">Indacaterol/glycopyrronium bromide</span> Combination drug

Indacaterol/glycopyrronium bromide, sold under the brand name Ultibro Breezhaler among others, is a fixed-dose combination medication for inhalation consisting of the following two active ingredients:

Aclidinium bromide/formoterol, sold under the brand names Duaklir and Brimica, is a fixed-dose combination medication for inhalation, used in the management of chronic obstructive pulmonary disease (COPD). It consists of aclidinium bromide, a long-acting muscarinic antagonist, and formoterol, a long-acting β2 agonist.

Beclometasone/formoterol/glycopyrronium, sold under the brand name Trimbow among others, is an inhalable fixed-dose combination medication for the treatment of chronic obstructive pulmonary disease (COPD) and asthma. It contains beclometasone dipropionate, formoterol fumarate dihydrate, and glycopyrronium bromide.

Indacaterol/glycopyrronium bromide/mometasone, sold under the brand name Enerzair Breezhaler among others, is an inhalable fixed-dose combination medication for the treatment of asthma. It contains indacaterol as acetate, glycopyrronium bromide, and mometasone furoate.

References

  1. ↑ "Fluticasone / umeclidinium / vilanterol (Trelegy Ellipta) Use During Pregnancy". Drugs.com. 13 June 2019. Retrieved 4 February 2020.
  2. ↑ "Search Page - Drug and Health Product Register". 23 October 2014.
  3. 1 2 "Trelegy Ellipta 92 micrograms/55 micrograms/22 micrograms inhalation powder, pre-dispensed - Summary of Product Characteristics (SmPC)". (emc). 30 October 2019. Retrieved 4 February 2020.
  4. 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 "Trelegy Ellipta- fluticasone furoate, umeclidinium bromide and vilanterol trifenatate powder". DailyMed. GlaxoSmithKline. 15 May 2019. Retrieved 11 July 2020.
  5. 1 2 3 4 "Temybric Ellipta EPAR". European Medicines Agency (EMA). 24 April 2019. Retrieved 11 July 2020.
  6. 1 2 "Trelegy Ellipta (fluticasone furoate 100 mcg, umeclidinium 62.5 mcg, and vilanterol 25 mcg) Inhalation Powder". U.S. Food and Drug Administration (FDA). 20 February 2018. Retrieved 4 February 2020.
  7. ↑ Lipson DA, Barnhart F, Brealey N, Brooks J, Criner GJ, Day NC, et al. (May 2018). "Once-Daily Single-Inhaler Triple versus Dual Therapy in Patients with COPD". The New England Journal of Medicine. 378 (18): 1671–1680. doi: 10.1056/NEJMoa1713901 . PMID   29668352.
  8. ↑ "The Top 300 of 2020". ClinCalc. Retrieved 7 October 2022.
  9. ↑ "Fluticasone; Umeclidinium; Vilanterol - Drug Usage Statistics". ClinCalc. Retrieved 7 October 2022.
  10. ↑ "Recommendations - Chronic obstructive pulmonary disease in over 16s: diagnosis and management". www.nice.org.uk. National Institute for Health and Care Excellence. 5 December 2018. Retrieved 12 July 2020.
  11. ↑ "2020 GOLD Pocket Guide" (PDF). goldcopd.org. Global Initiative for Chronic Obstructive Lung Disease. Retrieved 12 July 2020.
  12. ↑ Noakes T (December 2002). "Medical aerosol propellants". Journal of Fluorine Chemistry. 118 (1–2): 35–45. doi:10.1016/S0022-1139(02)00191-4.
  13. ↑ Parri G, Nieri D, Roggi MA, Vagaggini B, Celi A, Paggiaro P (December 2018). "Fluticasone furoate, umeclidinium bromide, and vilanterol as a combination therapy for chronic obstructive pulmonary disease". Expert Review of Respiratory Medicine. 12 (12): 997–1005. doi:10.1080/17476348.2018.1548936. PMID   30463451. S2CID   53782419.
  14. ↑ Liu D, Ahmet A, Ward L, Krishnamoorthy P, Mandelcorn ED, Leigh R, et al. (August 2013). "A practical guide to the monitoring and management of the complications of systemic corticosteroid therapy". Allergy, Asthma, and Clinical Immunology. 9 (1): 30. doi: 10.1186/1710-1492-9-30 . PMC   3765115 . PMID   23947590.
  15. 1 2 "Trelegy Ellipta EPAR". European Medicines Agency (EMA). 24 May 2019. Retrieved 4 February 2020.
  16. 1 2 "Elebrato Ellipta EPAR". European Medicines Agency (EMA). 17 September 2018. Retrieved 19 June 2020.
  17. ↑ "Fluticasone furoate". pubchem.ncbi.nlm.nih.gov. National Library of Medicine. Retrieved 12 July 2020.
  18. ↑ "Fluticasone". pubchem.ncbi.nlm.nih.gov. National Library of Medicine. Retrieved 12 July 2020.
  19. ↑ "Umeclidinium bromide". pubchem.ncbi.nlm.nih.gov. National Library of Medicine. Retrieved 12 July 2020.
  20. ↑ "Vilanterol". pubchem.ncbi.nlm.nih.gov. National Library of Medicine. Retrieved 12 July 2020.
  21. 1 2 "Updated Information: April 21, 2020: Meeting of the Pulmonary-Allergy Drugs Advisory Committee Meeting Announcement". U.S. Food and Drug Administration (FDA). 21 April 2020. Retrieved 12 July 2020.
  22. ↑ Fagg J (23 March 2020). "Go or no go? Covid-19 upstages US regulatory decisions". Evaluate.com. Retrieved 12 July 2020.
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.